Microbiome and Allergic Diseases

Mariona Pascal1†, Marina Perez-Gordo2,3†, Teresa Caballero4, Maria M. Escribese2, M. Natividad Lopez Longo5, Olga Luengo6, Luis Manso7, Victor Matheu8, Elena Seoane9, Miguel Zamorano10, Moisés Labrador6 and Cristobalina Mayorga11*

1 Immunology Department, Centro de Diagnóstico Biomédico, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, ARADyAL, Barcelona, Spain, 2 Basic Medical Science Department, Faculty of Medicine, CEU San Pablo University, ARADyAL, Madrid, Spain, 3 Institute of Applied and Molecular Medicine (IMMA), Faculty of Medicine, CEU San Pablo University, Madrid, Spain, 4 Hospital Universitario La Paz, Madrid, Spain, 5 Hospital Universitario de Araba, Vitoria, Spain, 6 Hospital Vall d’Hebron, Barcelona, Spain, 7 Hospital Universitario del Sureste, Madrid, Spain, 8 Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 9 Hospital Universitario Gregorio Marañón, Madrid, Spain, 10 Hospital Universitario Ramón y Cajal, Madrid, Spain, 11 Research Laboratory and Allergy Unit, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, Universidad de Málaga, ARADyAL, Malaga, Spain

Allergic diseases, such as respiratory, cutaneous, and food allergy, have dramatically increased in prevalence over the last few decades. Recent research points to a central role of the microbiome, which is highly influenced by multiple environmental and dietary factors. It is well established that the microbiome can modulate the immune response, from cellular development to organ and tissue formation exerting its effects through multiple interactions with both the innate and acquired branches of the immune system. It has been described at some extent changes in environment and nutrition produce dysbiosis in the gut but also in the skin, and lung microbiome, inducing qualitative and quantitative changes in composition and metabolic activity. Here, we review the potential role of the skin, respiratory, and gastrointestinal tract (GIT) microbiomes in allergic diseases. In the GIT, the microbiome has been proven to be important in developing either effector or tolerant responses to different antigens by balancing the activities of Th1 and Th2 cells. In the lung, the microbiome may play a role in driving asthma endotype polarization, by adjusting the balance between Th2 and Th17 patterns. Bacterial dysbiosis is associated with chronic inflammatory disorders of the skin, such as atopic dermatitis and psoriasis. Thus, the microbiome can be considered a therapeutic target for treating inflammatory diseases, such as allergy. Despite some limitations, interventions with probiotics, prebiotics, and/or synbiotics seem promising for the development of a preventive therapy by restoring altered microbiome functionality, or as an adjuvant in specific immunotherapy.

Keywords: microbiome, microbiota, allergy, allergic diseases, prebiotics, probiotics, synbiotics

INTRODUCTION

Allergic diseases, include heterogeneous inflammatory pathologies such as respiratory and food allergies (FA), which are characterized by an immunological response with T lymphocytes producing IL-4, IL-5, and IL-13 and low production of IFN-γ (Th2) (1) and others producing IL-9 and IL-10 (Th9) (2) as the main effector T cells. They promote the induction of other effector cells involved in allergic inflammation, such as mast cells, basophils, and eosinophils (1). These diseases have dramatically increased in prevalence over the last few decades (3–6) and recent research points to a central role of the microbiota (7, 8). It is well established that the microbiome can modulate the immune
response, from cellular development to organ and tissue formation (9) exerting its effects through multiple interactions with both the innate and acquired branches of the immune system. In the late 80s, Dr. Strachan proposed what is now referred to as the “hygiene-hypothesis” (10), in which changes in environment and nutrition produce a dysbiosis in the skin, gut, or lung microbiome inducing qualitative and quantitative changes in composition and metabolic activity (11, 12). Furthermore, it was proposed that a lower incidence of infection in early childhood, which may be associated with low microbiota diversity, could explain the increase in prevalence of atopic diseases (13). It should be pointed out that the hygiene hypothesis has not been found to apply to individual hygiene [no relation between personal or home cleanliness and increased risk of asthma or allergy has been found (14)], but to independent host factors such as number of older siblings, contact with pets and rural versus urban living, all of which have been shown to affect microbiome composition and the development of immunologic tolerance (15). Today, the use of bacterial culture-independent tools such as next-generation sequencing to identify different microbes has permitted the investigation of complex populations and their roles in health and disease. Here, we review the potential role of the skin, respiratory, and gastrointestinal tract (GIT) microbiomes in allergic diseases.

MICROBIOME

The term “microbiome” refers to the microorganisms that live on or inside another organism. They interact with each other and with their host and can be classified as beneficial (symbiotic) or dangerous (pathogenic) (16). Microbiome in humans can account for 90% of the cells by a ratio of 10:1 (17). New studies point out that the number of bacteria in the body is of the same order as the number of human cells (18). Most of these microorganisms inhabit the gut. The microbiome effectively adds a huge amount of genes to the human genome, potentially increasing it up to 200 times (19). As a result, the composition of the human microbiome could be important in the context of health or disease.

Human Gut Microbiome and Implications in Food Allergy

The GIT has a very important immune function in developing either effector or tolerant responses to different antigens by balancing the activities of Th1 and Th2 cells as well as regulating Th17 and T regulatory (Treg) cells in the lamina propria (20–23). Immune dysfunction in allergic diseases such as asthma and atopy seems to be related to differences in the function and composition of the gut microbiome (24).

The gut microbiome constitutes a highly complex ecosystem which includes eukaryotic fungi, viruses, and some archaea, although bacteria are the most prominent components (25). Its composition is generally formed during the first 3 years of life (26); however, recent work has suggested that its colonization may begin in utero (27), contrary to the widely held dogma of the fetus as a sterile environment. Despite its early formation, its composition is highly dynamic and dependent on host-associated factors such as age, diet, and environmental conditions (26, 28–31) with the major phyla being Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria. The gut microbiome is not homogeneous throughout the GIT, showing higher diversity in the oral cavity and intestine, and lower diversity in the stomach, mainly because of the acid environment (32). Aerobic species are mainly located in the upper small intestine and anaerobic species in the colon (33).

Most antigens in the GIT come from dietary factors and gut microbiota, both of which can affect immune tolerance being the promotion of Treg cells to these dietary factors crucial to avoid an immune response to dietary antigens (34). Alterations in GIT bacterial levels or diversity (dysbiosis) can disrupt mucosal immunological tolerance, leading to allergic diseases including FA (35) and even asthma (36–38). Moreover, low IgA levels at the intestinal surface barrier can also contribute to FA. In fact, low microbiota levels and IgA appear to be related: gut microbiota can stimulate dendritic cells (DCs) in the Peyers's patches (digestive type of mucosa lymphoid-associated tissue) to activate B cells, leading to specific IgA antibodies production through class switching (39). This stimulation may occur through the production by members of the microbiome of metabolites, such as short chain fatty acids (SCFAs). Thus, the immune tolerance network in the intestinal lumen can be considered to include the gut microbiota, their metabolic products, dietary factors, epithelial cells, DCs, IgA antibodies, and regulatory T cells (Figure 1).

Several factors associated with dysbiosis may influence FA, such as cesarean versus vaginal delivery (40), low versus rich fiber diet (41), breastfeeding (42), and/or early-life-antibiotic exposure, all of which affect bacterial load and diversity.

Once thought to be almost sterile, the esophagus has been shown to comprise around 300 bacteria species. Significant differences in the microbial composition of children with active esophageal inflammation caused by eosinophilic esophagitis compared with controls have been reported (43). Importantly, both the degree of inflammation and the treatment regimen seem to impact the esophageal microbiota (43).

Human Lung Microbiome and Implications in Respiratory Allergy

As with the esophagus and fetus, the lung has long been thought of as sterile; however, recent evidence has shown it to harbor various bacteria phyla, including Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria, even in healthy subjects (44). Similar to the gut, the lung microbiome changes rapidly in the first years of life, before beginning to stabilize (45, 46). Colonization occurs gradually in healthy children, starting with Staphylococcus or Corynebacterium, followed by Moraxella or Alloiococcus (46). A breakdown in the development of the commensal population can lead to dysregulation of the IgE–basophil axis, with elevated serum IgE concentrations and increased of circulating basophil populations as has been described in murine models of allergic airway disease (47). Importantly, this link was found to be B-cell intrinsic and dependent on the MYD88 pathway. Moreover, the lung microbiome may also play a role in driving asthma endotype polarization, by adjusting the balance between Th2 and Th17 patterns. Enterococcus faecalis can suppress Th17 immunity and symptoms of allergic airway disease, and thus it has even been considered a potential therapeutic agent for both asthma and Th17 immunity (48).
Differences in levels and diversity of the lung microbiome have been found between healthy people and patients with asthma and allergic diseases, with an increase of Proteobacteria in the latter; moreover, their presence has been linked to increased severity of asthma probably through the upregulation of Th17-related genes (49, 50).

Early colonization with Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae has been associated with recurrent wheezing and asthma (45, 46, 51, 52). Importantly, as well as bacteria, viruses will also influence asthma development, as has been demonstrated with human rhinovirus infections of the nasopharynx in early-life (46). In addition, other associations such as helminths may be protective for asthma, as helminth infections have been shown to increase the microbiota diversity (53). Associations have been found between the composition of the lung and gut microbiome and the risk of respiratory allergic disease development (54) indicating that both gut and lung mucosa may function as a single organ, sharing immunological functions (44).

**Skin Microbiome and Cutaneous Allergic Diseases**

Bacterial dysbiosis is associated with chronic inflammatory disorders of the skin, such as atopic dermatitis (AD) and psoriasis (55). The composition of the skin microbiota depends on the body site samples (56). The relevance of AD, often associated with other allergic diseases, has significantly increased in the last few decades. Outgrowths of Staphylococcus and reductions of other communities like Streptococcus or Propionibacterium species correlate with AD flares (57). On the other hand, skin commensal Acinetobacter species have been reported to protect against allergic sensitization and inflammation, playing an important role in tuning the balance of Th1, Th2, and anti-inflammatory responses to environmental allergens (58). Interestingly, studies of cutaneous allergic diseases have found an association with gut microbiome dysbiosis (59), although the underlying mechanisms are still unclear. An initial study of 90 patients with established AD found enrichment for Faecalibacterium prausnitzii and decreased levels of SCFAs in the gut (60).

Therefore, we can summarize that changes in environment and diet produce dysbiosis in gut, skin, and/or lung microbiome inducing qualitative and quantitative changes in the microbiota which directly affect the immunological mechanisms implicated in the prevention of allergic diseases (Figure 2).

**FACTORS AFFECTING MICROBIOME DIVERSITY**

**Childbirth**

The mode of delivery in childbirth can produce profound differences in the infant gut microbiome, with lower level of Escherichia coli, Bifidobacterium, and Bacteroides species in children born through cesarean section compared with those delivered vaginally (28, 61, 62). Cesarean-born infants typically have a microbiome enriched with Staphylococcus and Streptococcus, comparable with the maternal skin microbiome (63). These differences appear to be associated with higher risk of allergic diseases and asthma (64–66). Transfer of maternal vaginal microbes at birth may
mitigate these effects (67). Time of gestation may also be a factor: premature births are associated with alterations of the gut microbiome, but not atopic sensitization (68).

**Importance of Early-Life Microbiome**

There is mounting evidence that early-life exposure is critical for the microbiome and that gut microbial dysbiosis heavily influences immune system development (53). Potential factors include perinatal exposure to maternal or infant diet, antibiotic use, and contact with older siblings (16). Data from different populations show that the highest interindividual microbial variability occurs during the first 3 years of age (26). Noteworthy, contact with the microbiome can start before birth, since a low-abundance microbiota in the placenta (69) and meconium (70, 71) have been found.

Microbial exposure during the first months of life induces the activation of the innate immune system in different ways, with consequences for FA. Early inoculation with spore-forming *Clostridium* class IV and XIV species (72) and other bacteria (53) leads to decreased levels of circulating IgE in adulthood. Conversely, 3-week-old neonates with a higher fecal burden of *Clostridium difficile* and a higher ratio of *C. difficile* to *Bifidobacterium* showed increased numbers of skin test positive results to food and aero-allergens (73). Similarly, high levels of fecal *E. coli* in infants during their first month are associated with IgE-mediated eczema (74, 75).

Remarkably, the same colonization pattern can have different consequences at different ages. For example, colonization of *S. pneumoniae*, *H. influenzae*, or *M. catarrhalis* within the first month of life increases the risk of asthma, leading to high counts of atopic markers such as eosinophils and serum IgE, but not when colonization occurs at 12 months (45).

Furthermore, respiratory tract infections during early-life are associated with asthma development (76, 77). This may be because viral infections favor other opportunistic respiratory pathogens such as *M. catarrhalis* and *S. pneumoniae*, increasing the risk of asthma exacerbations (78). Other possible mechanisms may involve respiratory rhinovirus interacting with airway epithelial cells, increasing IL-25 and IL-33 production and contributing to Th2 immune responses (79). This is in line with the higher levels of house dust mite-specific IgE found in children infected with rhinovirus (80). Moreover, rhinovirus infection can also induce mucus hypersecretion and airway hyperresponsiveness in neonatal mice compared with adults (81).

**Diet and Microbiome Metabolic Products**

Another key factor influencing gut microbiome diversity is infant feeding, and especially breastfeeding, which has been shown to increase colonization by *Lactobacilli* and *Bifidobacteria* (82). Breast milk contains oligosaccharides and a wide range of fatty acids, which will affect the gut microbiome and its capacity to produce metabolites that protect against allergies and asthma (83) through the development of Treg cells (84). This effect is also produced by the intake of unprocessed milk during the first year of life, probably related to higher levels of peptides in the serum fraction and unsaturated omega-3 fatty acids (85). Other dietary components such as polyphenols and fish oils are also important for microbiome diversity (86–88).

Some noteworthy bacteria, such as *Lachnospiraceae* and *Ruminococcaceae*, can also influence the gut microbiome by producing SCFAs—including propionate, butyrate, and acetate—through fermentation of complex dietary carbohydrates. Importantly, besides acting as an essential energy source for gastrointestinal colonocytes, these acids exert various anti-inflammatory effects on the immune system that can modulate FA and respiratory diseases (89, 90), by increasing epithelial barrier function (91), and inducing Treg cells (colonial CD103+FoxP3+ cells), DCs precursors, and IL-10 production (8, 90).

**Importance of Exposure to Antibiotics**

The introduction of antibiotics in the 1950s is associated with an increasing incidence of allergy. This is thought to be causes by antibiotics inducing dysbiosis which has been shown to directly impact the development of AD (92) and asthma (48). The age of initial exposure could be important since maternal intake of antibiotic during pregnancy increases the risk of allergy in children (93), and antibiotic use in the first month of life has been associated with cow’s milk allergy (94). Intrapartum antibiotics have been shown to lead to a modified microbiome in children at 3 and 12 months (95). Other studies showed that antibiotics affect the microbiome in older subjects (96, 97). Antibiotic administration is associated with severe allergic airway inflammation in neonates, but not in adults (98).

Even low doses of antibiotics can affect microbiome composition (99); however, the associations between antibiotic consumption and allergic diseases increase with the number of antibiotics prescribed, and variable effects have been found for different antibiotic families. Some studies have indicated...
that betalactam antibiotics are the most common triggers when FA is diagnosed before 2 years of age, while macrolides are associated with FA when it is diagnosed later (100). For asthma, further studies are needed to clarify whether it is the infection rather than the antibiotics themselves that increase susceptibility (101).

**INTERVENTIONS**

The microbiota can be considered a therapeutical target for treating allergy; moreover, certain species can be used to enhance tolerance response induction. Different approaches for restoring the microbiome involve probiotics, prebiotics, and synbiotics.

**Probiotics**

According to the Food and Agriculture Organization of the United Nations and the World Health Organization, probiotics are defined as “live microorganisms which, when administered in adequate amounts, confer a health benefit to the host” (102). They do so by promoting the appropriate balance of gut microbiota. The health benefits attributed to one probiotic strain are not necessarily applicable to another one even within one given species (103). Furthermore, the effectiveness may depend on the time of intervention and aspects of the current microbiota composition. In fact, different studies have shown that timing is crucial (104).

In the case of FA, co-administration of bacterial adjuvants with oral immunotherapy (OIT) has been suggested as a potential treatment. Probiotic therapy with *Lactobacillus rhamnosus* increases efficacy when co-administered with peanut OIT—producing desensitization in 82% of treated patients (105)—or with hydrolyzed casein in milk allergic patients, in which an increase of fecal butyrate levels were found (106, 107). However, other strains of *Lactobacilli* and/or *Bifidobacteria* did not demonstrate any effect in preventing allergic diseases (106, 107). Some investigations have shown that the oral administration of probiotics may benefit allergic rhinitis patients (108–110); similarly, local nasal administration of *Lactococcus lactis* NZ9000 can affect local and systemic immune responses against *S. pneumoniae* (111). However, Ivory et al. reported that even oral delivery of *Lactobacillus casei* Shiroti modified the immune system of allergic individuals (110), these modifications did not have a significant impact on the allergic status (112), highlighting the fact that analysis of immune parameters *per se* is not a real indicator of the therapeutical properties of the probiotics.

It has been suggested that probiotics can help preventing eczema and they also show some beneficial effects for other allergic diseases including asthma (113–117); furthermore, another approach based on the intranasal application of bacterial products (endotoxin or flagellin) has demonstrated immunomodulatory ability, mimicking the effect of probiotics, for the lung in different animal models, reducing experimental asthma by either re-establishing the expression of the ubiquitin-modifying enzyme A20 at the endothelial barrier or inducing Tregs (118, 119).

Therefore, it seems that the optimal time periods to apply probiotic intervention are before, during, and just after birth represents. Nevertheless, more studies, using clinical trial methodologies when possible, should be carried out to confirm these findings and determine the optimal probiotics to use.

**Prebiotics**

Prebiotics are non-digestible food components that benefit the host by selectively stimulating the growth and activity of microorganisms. Studies have shown that fibers and oligosaccharides can improve immunity and metabolism (8) and that the treatment of pregnant and lactating mice increases the proportions of *Lactobacillus* and *Clostridium leptum* and promotes a long-term protective effect against FA in the offspring (120).

Studies evaluating the effect of fiber/oligosaccharide intake in modulating asthma (121–123) have shown heterogeneous results, with one study reporting a reduction of wheezing (121) but others reporting no effect (122, 123). A recent Cochrane review has shown that although the addition of prebiotics to infant food may reduce the risk of eczema, it is not clear whether their use may affect other allergic diseases including asthma (124).

**Synbiotics**

When the use of a combination of prebiotics and probiotics produce synergistic health benefits it is described as a symbiotic. In FA mice models, both the microbiome and diet can affect the development of food tolerance by the induction of Treg cells (34). In cow’s milk allergy, it has been demonstrated that treatment with extensively hydrolyzed casein formula plus *L. rhamnosus* GG promotes tolerance through changes in the infant gut microbiome (89).

A recent meta-analysis has shown their beneficial effects for eczema treatment (125). However, further well-conducted, randomized, placebo-controlled longitudinal studies are still needed in this area (126).

**CONCLUSION**

The microbiota is a highly dynamic environment influenced by multiple environmental and dietary factors, with a complex role in allergic diseases. Further studies with larger number of well-characterized patients and controls are needed to dissect the role of microbiome in allergic diseases are the performance. Despite some limitations, interventions with probiotics, prebiotics, and/or synbiotics show promise for the development of a preventive therapy, either by restoring altered microbiome functionality due to dysbiosis or as a boosting of immunological system in specific immunotherapy. However, the field is still relatively new and we expect many key findings to be made in the next few years. Detailed prospective, randomized, placebo-controlled studies will be essential for this purpose.

**AUTHOR’S NOTE**

All authors belongs to the Immunology Committee of the Spanish Society of Allergy and Clinic Immunology (SEAIC).

**AUTHOR CONTRIBUTIONS**

CM, MP and MP-G conceived and designed this manuscript and were involved in manuscript production contributing equally to
this work. TC, MME, MNLL, OL, LM, VM, ES, MZ and ML have read, revised and approved the manuscript.

ACKNOWLEDGMENTS
This work was supported by ISCIII (project number P117/01087) cofounded by FEDER for the thematic network and cooperative research centers ARADYAL (RD16/0006/0007, RD16/0006/0015, and RD16/0006/0001). All the authors acknowledge Tomás Barker for language revision.

FUNDING
This article have been paid by the Sociedad Española de Alergología e Imunología Clínica (SEAIC) Foundation.

REFERENCES
1. Akdis CA. Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol (2006) 18(6):718–26. doi:10.1016/j.coi.2006.09.016
2. Veldhoen M, Wyatt-Coke C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta retropgrames the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol (2008) 9(12):1341–6. doi:10.1038/ni.1659
3. Akinbami LJ, Simon AE, Rossen LM. Changing trends in asthma prevalence among children. Pediatrics (2016) 137(1). doi:10.1542/peds.2015-2354
4. Prescott SL, Pawankar R, Allen KJ, Campbell DE, Sinn J, Fiocchi A, et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J (2013) 6(1):21. doi:10.1186/1939-4551-6-21
5. Savage J, Johns CR. Food allergy: epidemiology and natural history. Immunol Allergy Clin North Am (2015) 35(1):45–59. doi:10.1016/j.iac.2014.09.004
6. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol (2014) 133(2):291–307; quiz 308. doi:10.1016/j.jaci.2013.11.020
7. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol (2009) 7(12):887–94. doi:10.1038/nrmicro2245
8. Trompetta A, Gottlieb H, Yadaia K, Silchenstel AK, Sprenger N, Gombr C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med (2014) 20(2):159–66. doi:10.1038/nm.3444
9. Palm NW, de Zoete MR, Flavell RA. Immune-microbiota interactions in health and disease. Clin Immunol (2015) 159(2):122–7. doi:10.1016/j.clim.2015.05.014
10. Strachan DP. Hay fever, hygiene, and household size. BMJ (1989) 299(6710):1259–60. doi:10.1136/bmj.299.6710.1259
11. Daley D. The evolution of the hygiene hypothesis: the role of early-life exposure to viruses and microbes and their relationship to asthma and allergic diseases. Curr Opin Allergy Clin Immunol (2014) 14(3):390–6. doi:10.1097/ACI.0000000000000101
12. Platts-Mills TA. The allergy epidemic: 1870–2010. J Allergy Clin Immunol (2013) 136(1):3–13. doi:10.1016/j.jaci.2015.03.048
13. Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson W, Bjoern-Fuhlendorf C, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med (2011) 364(8):701–9. doi:10.1056/NEJMoa1007302
14. Marsland BI, Salami O. Microbiome influences on allergy in mice and humans. Curr Opin Immunol (2015) 36:94–100. doi:10.1016/j.coi.2015.07.005
15. Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. J Allergy Clin Immunol (2013) 132(3):601–607.e8. doi:10.1016/j.jaci.2013.05.043
16. Riisar A. The human microbiome, asthma, and allergy. Allergy Asthma Clin Immunol (2015) 11:35. doi:10.1186/s13223-015-0102-0
17. Ley RE, Peterson DA, Gordon JL. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell (2006) 124(4):837–48. doi:10.1016/j.cell.2006.02.017
18. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol (2016) 14(8):e1002533. doi:10.1371/journal.pbio.1002533
19. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JL. The human microbiome project. Nature (2007) 449(7164):804–10. doi:10.1038/nature06244
20. O’Mahony C, Scully P, O’Mahony D, Murphy S, O’Brien F, Lyons A, et al. Commensal-induced regulatory T cells mediate protection against pathogenic—stimulated NF-kappaB activation. PLoS Pathog (2008) 4(8):e1000112. doi:10.1371/journal.ppat.1000112
21. Ostman S, Rask C, Wold AE, Hultkrantz S, Telema E. Impaired regulatory T cell function in germ-free mice. Eur J Immunol (2006) 36(9):2336–46. doi:10.1002/eji.200535244
22. Ivanov II, Atarashi K, Mitsuji N, Brodie EL, Shima T, Kojima S, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 139(3):485–98. doi:10.1016/j.cell.2009.09.033
23. Ivanov II, Frutos Rde L, Mitsuji N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe (2008) 4(4):337–49. doi:10.1016/j.chom.2008.09.009
24. Muir AB, Benitez AJ, Dods K, Spergel JM, Fillon SA. Microbiome and its impact on gastrointestinal atopy. Allergy (2016) 71(9):1256–63. doi:10.1111/ al.13294
25. Power SE, O’Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr (2014) 111(3):387–402. doi:10.1017/ S0007114513002560
26. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature (2012) 486(7402):222–7. doi:10.1038/nature10153
27. Mole L, Gomez M, Heilig H, Bustos G, Fuentes S, de Vos W, et al. Bacterial diversity in meconium of preterm neonates and evolution of their fecal microbiota during the first month of life. PLoS One (2013) 8(6):e69696. doi:10.1371/journal.pone.0069696
28. Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe (2015) 17(5):690–703. doi:10.1016/j.chom.2015.04.004
29. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels JG, et al. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr (2015) 60(4):424–33. doi:10.1097/MPG.0000000000000356
30. Qin J, Li W, Zhang M, Hanov SA, Gorbachson C, Celinhan C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 464(7285):59–65. doi:10.1038/nature08821
31. Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R. Regional specialization within the intestinal immune system. Nature (2016) 532(7597):177–80. doi:10.1038/nature17378
32. Aitoro R, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Granata V, et al. Gut microbiota as a target for preventive and therapeutic intervention against food allergy. Nutrients (2017) 9(7):E567. doi:10.3390/nu9070762
33. Abrahamsson TR, Jacobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol (2012) 129(2):e341–2. doi:10.1016/j.jaci.2011.02.055
37. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy (2014) 44(6):842–50. doi:10.1111/ceu.12361
38. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol (2011) 128(3):e641–5. doi:10.1016/j.jaci.2011.04.060
39. Suzuki K, Kawamoto S, Maruya M, Fagarasan S. GALT: organization and dynamics leading to IgA synthesis. Adv Immunol (2010) 107:153–85. doi:10.1016/B978-0-12-381300-8.00006-X
40. Papathoma E, Triga M, Fouzas S, Dimitriou G. Cesarean section delivery and development of food allergy and atopic dermatitis in early childhood. Pediatr Allergy Immunol (2016) 27(4):419–24. doi:10.1111/pai.12552
41. Grimshaw KE, Maskell J, Oliver EM, Morris RC, Foote KD, Mills EN, et al. Diet and food allergy development during infancy: birth cohort study findings using prospective food diary data. J Allergy Clin Immunol (2014) 133(2):511–9. doi:10.1016/j.jaci.2013.05.035
42. Muraro A, Halken S, Arshad SH, Beyer K, Dubois AE, Du Toit G, et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy (2014) 69(5):590–601. doi:10.1111/all.12398
43. Benitez AJ, Hoffmann C, Muir AB, Dods KK, Spergel JM, Bushman FD, et al. Inflammation-associated microbiota in pediatric eosinophilic esophagitis. J Allergy Clin Immunol (2015) 3:23. doi:10.1016/j.jaci.2015.08.005-6
44. Segal LN, Blaser MJ. A brave new world: the lung microbiota in an era of change. Ann Am Thorac Soc (2014) 11(Suppl 1):S21–7. doi:10.1513/AnnalsATS.201303189MG
45. Bisgaard H, Hermansen MN, Buchvald F, L halkjær LB, Loland L, Halkjaer LB, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med (2007) 357(15):1487–95. doi:10.1056/NEJMoA072632
46. Teo SM, Mok D, Pham K, Kuel M, Serralha M, Troy N, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe (2015) 17(5):704–15. doi:10.1016/j.chom.2015.03.008
47. Hill DA, Siracusa MC, Abt MC, Kim BS, Kobuley D, Kubo M, et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat Med (2012) 18(4):538–46. doi:10.1038/nm.2657
48. Adami AJ, Bracken SJ. Breathing better through bugs: asthma and the microbiome. J Biol Med (2016) 89(3):309–7. doi:10.1016/j.jaci.2015.08.021
49. Hilty M, Burke C, Asfour E, Kuo J, Du Toit G, et al. Early gut microbiota variations in early gut microbial colonization are associated with allergen-specific immunoglobulin E but not atopic eczema at 2 years of age. Clin Exp Allergy (2011) 41(1):1545–54. doi:10.1111/j.1365-2222.2011.03817.x
50. Fyhrquist N, Ruokolainen L, Suomalainen A, Lehtimaki S, Veckman V, Ruuskanen O, et al. Gut microbiota composition and development of atopic eczema in 3 European birth cohorts. J Allergy Clin Immunol (2007) 120(2):343–50. doi:10.1016/j.jaci.2007.05.018
51. Koren O, Lidgorska E, Einarsson E, Zaidi S, Fenton J, Leung DYM, et al. Effect of early infant probiotic intervention on the development of atopic eczema and asthma in infants: a randomised controlled trial. Lancet (2009) 374(9688):455–61. doi:10.1016/S0140-6736(09)60181-9
52. Karlstrom A, Lindgren H, Hildingsson I. Maternal and infant outcome after caesarean section without recorded medical indication: findings from a Swedish case-control study. BJOG (2015) 122(5):590–601. doi:10.1111/1471-0528.13129
53. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the gut microbiota. Proc Natl Acad Sci U S A (2010) 107(26):11957–62. doi:10.1073/pnas.1006811107
54. Kristensen K, Henriksen L. Cesarean section and disease associated with immune function. J Allergy Clin Immunol (2016) 137(2):587–90. doi:10.1016/j.jaci.2015.07.040
55. Hilty M, Burke C, Asfour E, Kuo J, Du Toit G, et al. Early gut microbiota variations in early gut microbial colonization are associated with allergen-specific immunoglobulin E but not atopic eczema at 2 years of age. Clin Exp Allergy (2011) 41(1):1545–54. doi:10.1111/j.1365-2222.2011.03817.x
56. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the gut microbiota. Proc Natl Acad Sci U S A (2010) 107(26):11957–62. doi:10.1073/pnas.1006811107
57. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the gut microbiota. Proc Natl Acad Sci U S A (2010) 107(26):11957–62. doi:10.1073/pnas.1006811107
58. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the gut microbiota. Proc Natl Acad Sci U S A (2010) 107(26):11957–62. doi:10.1073/pnas.1006811107
59. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the gut microbiota. Proc Natl Acad Sci U S A (2010) 107(26):11957–62. doi:10.1073/pnas.1006811107
76. Holt PG. The mechanism or mechanisms driving atopic asthma initiation: the infant respiratory microbiome moves to center stage. *J Allergy Clin Immunol* (2015) 136(3):15–22. doi:10.1016/j.jaci.2015.05.011
77. Smits HH, Hiiemaa PS, Prazeres da Costa C, Ege M, Edwards M, Garn H, et al. Microbes and asthma: opportunities for intervention. *J Allergy Clin Immunol* (2016) 137(3):690–7. doi:10.1016/j.jaci.2016.01.004
78. Kloooper KM, Lee WM, Pappas TE, Kang TJ, Vrits RE, Evans MD, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol* (2014) 133(5):e1301–3. doi:10.1016/j.jaci.2014.02.030
79. Beale J, Jayaraman A, Jackson DJ, Macintyre JD, Edwards MR, Walton RP, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. *Sci Transl Med* (2014) 6(256):256ea134. doi:10.1126/scitranslmed.3009124
80. Soto-Quiros M, Avila L, Platts-Mills TA, Hunt JF, Erdman DD, Carper H, et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. *J Allergy Clin Immunol* (2012) 129(6):499–505.e5. doi:10.1016/j.jaci.2012.03.040
81. Hong JY, Bentley JK, Chung Y, Lei J, Steenrod JM, Chen Q, et al. Neonatal breathing patterns in food allergic infants. *Cell Metab* (2015) 22(4):658–68. doi:10.1016/j.cmet.2015.04.006
82. Loss A, Apprich S, Waser M, Knefel W, Genuneit J, Buchele G, et al. The protective effect of farm milk consumption on childhood asthma and atopy: the GABRIELA study. *J Allergy Clin Immunol* (2011) 128(4):766–73.e4. doi:10.1016/j.jaci.2011.07.048
83. Lluis A, Depner M, Gaugler B, Saas P, Casaca VI, Raedler D, et al. Increased regulatory T-cell numbers are associated with farm milk exposure and lower astatic sensitization and asthma in childhood. *J Allergy Clin Immunol* (2014) 133(2):551–9. doi:10.1016/j.jaci.2013.06.034
84. Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. The relationship of early-life antibiotic use with asthma in at-risk children. *J Allergy Clin Immunol* (2014) 133(3):728–9. doi:10.1016/j.jaci.2014.03.006
85. Berni Canani R, Nocerino R, Terrin G, Frediani T, Lucarelli S, Cosenza L, et al. Formula selection for management of children with cow’s milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study. *J Pediatr* (2013) 163(3):771–777.e1. doi:10.1016/j.jpeds.2013.03.008
86. Hirsch AG, Pollak L, Glass TA, Poulsen MN, Bailey-Davis L, Mowery J, et al. Early-life antibiotic use and subsequent diagnosis of food allergy and allergic diseases. *Clin Exp Allergy* (2017) 47(2):236–44. doi:10.1111/cea.12807
87. Lapin B, Piorkowski J, Ownby D, Wagner-Cassanova C, Freels S, Chavez N, et al. The relationship of early-life antibiotic use with asthma in at-risk children. *J Allergy Clin Immunol* (2014) 134(3):728–9. doi:10.1016/j.jaci.2014.03.004
88. Sanders ME. Probiotics: definition, sources, selection, and uses. *Clin Infect Dis* (2008) 46(Suppl 2):S58–61. doi:10.1086/523341
89. Williams NT. Probiotics. *Am J Health Syst Pharm* (2010) 67(6):449–58. doi:10.2146/ajhp090168
90. Duchmann R, Kaiser I, Herrmann I, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). *Clin Exp Immunol* (1995) 102(3):448–55. doi:10.1111/j.1365-2249.1995.tb03836.x
91. Hirsch AG, Pollak L, Glass TA, Poulsen MN, Bailey-Davis L, Mowery J, et al. Early-life antibiotic use and subsequent diagnosis of food allergy and allergic diseases. *Clin Exp Allergy* (2011) 41(6):681–690. doi:10.1111/j.1365-2222.2009.03026.x
92. Costa DJ, Marteau P, Amouyal P, Poulsen LK, Hamelmann E, Carabauble M, et al. Efficacy and safety of the probiotic *Lactobacillus paracasei* LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GAZLEN2 Study). *Eur J Clin Nutr* (2014) 68(5):602–7. doi:10.1038/ejcn.2014.13
93. Ouweland AC, Nermes M, Collado MC, Rautonen N, Salminen S, Isolauri E. Specific probiotics alleviate atopic rhinitis during the birch pollen season. *World J Gastroenterol* (2009) 15(26):3261–8. doi:10.3748/wjg.15.3261
94. Ivory K, Chambers SJ, Pin C, Prieto E, Arques JL, Nicoletti C. Oral delivery of *Lactobacillus casei* Shirota modifies allergen-induced immune responses in allergic rhinitis. *Clin Exp Allergy* (2008) 38(8):1282–9. doi:10.1111/j.1365-2222.2008.03025.x
95. Medina M, Villena J, Salva S, Vintini E, Langella P, Alvarez S. Nasal administration of *Lactococcus lactis* improves local and systemic immune responses against *Streptococcus pneumoniae*. *Microbiol Immunol* (2008) 52(8):399–409. doi:10.1111/j.1348-0421.2008.00050.x
96. Ivory K, Wilson AM, Sankaran P, Westwood M, McCarrville J, Brockwell C, et al. Oral delivery of a probiotic induced changes at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a randomised clinical trial. *PLoS One* (2013) 8(11):e78650. doi:10.1371/journal.pone.0078650
97. Cuello-Garcia CA, Brozek JL, Fiocchi A, Pavankar R, Yepes-Nunez JJ, Terracciano L, et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin Immunol* (2015) 136(4):952–61. doi:10.1016/j.jaci.2015.04.031
114. Zuccotti G, Meneghin F, Aceti A, Barone G, Callegari ML, Di Mauro A, et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. *Allergy* (2015) 70(11):1356–71. doi:10.1111/all.12700

115. Tokunaga T, Ninomiya T, Osawa Y, Isomoto Y, Ito Y, Takabayashi T, et al. Factors associated with the development and remission of allergic diseases in an epidemiological survey of high school students in Japan. *Am J Rhinol Allergy* (2015) 29(2):94–9. doi:10.2500/aja.2015.29.4135

116. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet* (2001) 357(9262):1076–9. doi:10.1016/S0140-6736(00)04259-8

117. Elazab N, Mendy A, Gasana J, Vieira ER, Quizon A, Forno E. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. *Pediatrics* (2013) 132(3):e666–76. doi:10.1542/peds.2013-0246

118. Schuijs MJ, Willart MA, Vergote K, Gras D, Deswarte K, Eg M, et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. *Science* (2015) 349(6252):1106–10. doi:10.1126/science.aac6623

119. Shim JU, Lee SE, Hwang W, Lee C, Park JW, Sohn JH, et al. Flagellin suppresses experimental asthma by generating regulatory dendritic cells and T cells. *J Allergy Clin Immunol* (2016) 137(2):426–35. doi:10.1016/j.jaci.2015.07.010

120. Bouchaud G, Castan L, Chesne J, Braza F, Aubert P, Neunlist M, et al. Maternal exposure to GOS/inulin mixture prevents food allergies and promotes tolerance in offspring in mice. *Allergy* (2016) 71(1):68–76. doi:10.1111/all.12777

121. Arslanoglu S, Moro GE, Boehm G. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. *J Nutr* (2008) 138(6):1091–5. doi:10.1093/jn/138.6.1091

122. Kukkonen AK, Kuutunen M, Savilahti E, Pelkonen A, Malmberg P, Makela M. Airway inflammation in probiotic-treated children at 5 years. *Pediatr Allergy Immunol* (2011) 22(2):249–51. doi:10.1111/j.1399-3038.2010.01079.x

123. Arslanoglu S, Moro GE, Boehm G, Wieni E, Stahl R, Bertino E. Early neutral prebiotic oligosaccharide supplementation reduces the incidence of some allergic manifestations in the first 5 years of life. *J Biol Regul Homeost Agents* (2012) 26(3 Suppl):49–59.

124. Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. *Cochrane Database Syst Rev* (2013) (3):CD006474. doi:10.1002/14651858.CD006474.pub3

125. Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L, Garcia-Romero MT. Synbiotics for prevention and treatment of atopic dermatitis: a meta-analysis of randomized clinical trials. *JAMA Pediatr* (2016) 170(3):236–42. doi:10.1001/jamapediatrics.2015.3943

126. Tang ML, Lodge CJ. Examining the evidence for using synbiotics to treat or prevent atopic dermatitis. *JAMA Pediatr* (2016) 170(3):201–3. doi:10.1001/jamapediatrics.2015.4406

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Pascal, Perez-Gordo, Caballero, Escribese, Lopez Longo, Luengo, Manso, Mathers, Souane, Zamorano, Labrador and Mayorga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). No use, distribution or reproduction is permitted which does not comply with these terms.*